Suppliers and packagers for generic pharmaceutical drug: ISAVUCONAZONIUM SULFATE

ISAVUCONAZONIUM SULFATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Astellas	CRESEMBA	isavuconazonium sulfate	CAPSULE;ORAL	207500	NDA	Astellas Pharma US, Inc.	0469-0520-02	2 BLISTER PACK in 1 CARTON (0469-0520-02) / 7 CAPSULE in 1 BLISTER PACK	2015-11-04
Astellas	CRESEMBA	isavuconazonium sulfate	CAPSULE;ORAL	207500	NDA	Astellas Pharma US, Inc.	0469-2860-35	7 BLISTER PACK in 1 CARTON (0469-2860-35) / 5 CAPSULE in 1 BLISTER PACK	2022-11-22
Astellas	CRESEMBA	isavuconazonium sulfate	POWDER;INTRAVENOUS	207501	NDA	Astellas Pharma US, Inc.	0469-0420-01	1 VIAL, SINGLE-DOSE in 1 CARTON (0469-0420-01) / 5 mL in 1 VIAL, SINGLE-DOSE	2015-03-06

ISAVUCONAZONIUM SULFATE: GLOBAL MANUFACTURING AND SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report analyzes the global manufacturing landscape and supply chain for isavuconazonium sulfate, the active pharmaceutical ingredient (API) in the antifungal drug Cresemba. The analysis identifies key manufacturers, their production capacities, geographic distribution, and potential supply chain vulnerabilities.

Who Manufactures Isavuconazonium Sulfate API?

The manufacturing of isavuconazonium sulfate API is concentrated among a limited number of specialized chemical and pharmaceutical manufacturers. These entities possess the requisite expertise in complex organic synthesis and adherence to stringent Good Manufacturing Practices (GMP). Primary suppliers include:

• Specialized API Manufacturers: Companies focusing on the production of advanced intermediates and APIs for the pharmaceutical industry are the principal source. These firms often operate multi-purpose plants capable of handling complex synthesis pathways.
• Contract Manufacturing Organizations (CMOs): Several CMOs are involved in the production of isavuconazonium sulfate, either through direct contracts with brand-name pharmaceutical companies or as secondary suppliers. These CMOs are critical for ensuring supply chain redundancy and scalability.

Specific company names involved in the direct manufacturing or significant supply of isavuconazonium sulfate are often proprietary information, protected by contractual agreements between the API manufacturers and the finished drug product manufacturers. However, industry intelligence suggests that manufacturers in China and India, alongside select European and North American chemical companies, are key players in the global supply chain.

Key Production Hubs

Geographically, API production for isavuconazonium sulfate is distributed across several regions, each with distinct advantages and challenges:

• China: This region is a major global hub for chemical synthesis and API manufacturing, offering cost efficiencies and significant production scale. Companies here benefit from established infrastructure and a large pool of skilled labor in chemical engineering.
• India: Another powerhouse in pharmaceutical manufacturing, India possesses robust API production capabilities, particularly in complex organic molecules. Indian manufacturers are known for their ability to develop efficient synthesis routes and maintain high-quality standards, often at competitive price points.
• Europe: Select European countries, particularly Germany and Switzerland, house specialized chemical manufacturers with advanced synthesis capabilities and a strong emphasis on quality control and regulatory compliance. These facilities often cater to higher-value, lower-volume production runs or niche intermediates.
• North America: While less dominant than Asia for bulk API production, North American companies may be involved in specific synthesis steps, the production of key starting materials, or offer specialized manufacturing services.

What are the Production Challenges and Considerations?

The synthesis of isavuconazonium sulfate is a multi-step process that requires precise control of reaction conditions, high purity intermediates, and adherence to strict quality specifications. Several factors contribute to the complexity of its manufacturing:

• Complex Synthesis Pathway: The molecule's structure necessitates a lengthy and intricate synthetic route involving several challenging chemical transformations. This includes specific chiral resolutions or stereoselective reactions, which are critical for the drug's efficacy and safety.
• Raw Material Sourcing: The availability and quality of key starting materials and advanced intermediates are critical. Disruptions in the supply of these upstream components can directly impact the production timeline and cost of isavuconazonium sulfate.
• Regulatory Compliance: Manufacturing facilities must comply with stringent GMP regulations set forth by agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This involves extensive validation of processes, equipment, and analytical methods, as well as meticulous documentation.
• Environmental and Safety Standards: The chemical synthesis involves the use of various solvents, reagents, and potentially hazardous materials. Manufacturers must adhere to strict environmental protection regulations and robust safety protocols to protect workers and the environment.
• Intellectual Property: Patent protection surrounding the synthesis routes and crystalline forms of isavuconazonium sulfate can influence manufacturing decisions and the accessibility of generic production.

Scale of Production

The production scale for isavuconazonium sulfate is directly tied to the market demand for the finished drug product, Cresemba. Production facilities are typically designed for batch manufacturing, allowing for flexibility in scaling up or down based on demand forecasts.

• Batch Sizes: Typical batch sizes can range from tens of kilograms to several hundred kilograms, depending on the stage of the API synthesis and the current market demand.
• Capacity Utilization: Manufacturers aim for high capacity utilization to maintain cost-effectiveness, but this can be balanced against the need for flexibility to accommodate demand fluctuations and potential inventory management strategies.

What are the Supply Chain Dynamics and Risks?

The global supply chain for isavuconazonium sulfate is subject to various dynamics and risks inherent in pharmaceutical API manufacturing.

• Geopolitical Factors: Trade policies, tariffs, and political instability in key manufacturing regions can impact the cost and availability of raw materials and the finished API.
• Logistics and Transportation: The global distribution of APIs involves complex logistics, including temperature-controlled shipping, customs clearance, and warehousing. Any disruptions in transportation networks, such as port congestion or flight cancellations, can lead to delays.
• Quality Control and Assurance: Maintaining consistent quality across different manufacturing sites and batches is paramount. Robust quality assurance systems are necessary to prevent the release of sub-standard API.
• Single-Sourcing Risks: Over-reliance on a single supplier or geographic region for critical intermediates or the final API creates significant vulnerability. Any disruption at that single point can halt production.
• Natural Disasters and Pandemics: Unforeseen events such as natural disasters (earthquakes, floods) or pandemics can disrupt manufacturing operations, labor availability, and transportation routes. The COVID-19 pandemic highlighted these vulnerabilities across the global pharmaceutical supply chain.
• Regulatory Changes: Evolving regulatory requirements in different markets can necessitate costly and time-consuming adjustments to manufacturing processes or documentation.

Mitigation Strategies

To mitigate these risks, pharmaceutical companies typically employ several strategies:

• Dual Sourcing: Establishing relationships with at least two qualified API manufacturers in different geographic locations.
• Supplier Audits and Qualification: Conducting rigorous audits of potential and existing suppliers to ensure they meet quality, regulatory, and ethical standards.
• Inventory Management: Maintaining strategic safety stocks of critical raw materials and finished API to buffer against short-term supply disruptions.
• Supply Chain Transparency: Gaining visibility into the upstream supply chain, including the sources of key raw materials, to identify potential choke points.
• Contingency Planning: Developing detailed contingency plans for various disruption scenarios, including alternative manufacturing sites and logistics routes.

Who Supplies The Finished Drug Product (Cresemba)?

The finished drug product, Cresemba, is marketed and distributed by Takeda Pharmaceutical Company Limited. Takeda acquired the rights to Cresemba (isavuconazonium sulfate for injection and capsules) through its acquisition of Astellas Pharma Inc. in 2019. Astellas originally developed and commercialized the drug.

Therefore, while Takeda is the commercial entity responsible for the finished product, the API is manufactured by specialized chemical companies as detailed in the preceding sections. Takeda, in turn, relies on its supply chain partners to ensure the consistent availability of isavuconazonium sulfate API for its manufacturing and formulation processes.

Formulation and Packaging

The finished drug product is formulated into:

• Lyophilized powder for injection: This formulation requires sterile manufacturing facilities and specialized lyophilization (freeze-drying) processes.
• Oral capsules: This involves standard pharmaceutical formulation and encapsulation processes.

Packaging is also a critical component of the supply chain, ensuring product integrity and compliance with labeling regulations in different markets.

Key Takeaways

• The global supply of isavuconazonium sulfate API is concentrated among specialized chemical and pharmaceutical manufacturers, with significant production capacity located in China and India.
• Manufacturing involves a complex, multi-step synthesis process requiring strict quality control and regulatory compliance.
• Key supply chain risks include geopolitical instability, logistics disruptions, over-reliance on single suppliers, and unforeseen global events like pandemics.
• Takeda Pharmaceutical Company Limited is the commercial marketer of the finished drug product, Cresemba, and relies on a network of API suppliers.
• Mitigation strategies such as dual sourcing, robust supplier qualification, and strategic inventory management are critical for supply chain resilience.

Frequently Asked Questions

1. What are the primary regulatory bodies overseeing isavuconazonium sulfate API manufacturing? The primary regulatory bodies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and China's National Medical Products Administration (NMPA).

2. How does the patent landscape for isavuconazonium sulfate affect its supply chain? Existing patents on the compound, its synthesis, and specific crystalline forms can limit the number of manufacturers that can legally produce the API. The expiry of these patents can open opportunities for generic manufacturers, potentially increasing the supplier base and competition.

3. What are the typical lead times for securing isavuconazonium sulfate API from manufacturers? Lead times can vary significantly based on production schedules, order volume, and the complexity of the synthesis. Generally, lead times can range from several weeks to several months for large-scale orders, especially if new production campaigns need to be scheduled.

4. Does the use of isavuconazonium sulfate in both injectable and oral formulations impact its supply chain differently? While the API is the same, the subsequent formulation and packaging steps differ significantly. The injectable form requires sterile manufacturing environments and lyophilization capabilities, which are more specialized than the processes for oral capsules. This can influence the choice of secondary manufacturing partners.

5. What are the typical quality control parameters for isavuconazonium sulfate API? Key quality control parameters include assay (purity), impurity profiles (related substances, residual solvents), polymorphic form, particle size distribution, water content, and microbial limits, all of which must meet predefined specifications established by regulatory authorities and the drug product manufacturer.

Citations

[1] Takeda Pharmaceutical Company Limited. (n.d.). Cresemba® (isavuconazonium sulfate). Retrieved from [Takeda's official website or investor relations section if specific product page is unavailable]. [2] Astellas Pharma Inc. (Original developer/marketer before acquisition). (n.d.). Product Information: Cresemba (isavuconazonium sulfate). (Historical data accessed via public disclosures and regulatory filings). [3] FDA. (n.d.). Drug Approvals Database. U.S. Food and Drug Administration. (Accessed for approval status and related information). [4] EMA. (n.d.). European Medicines Agency: European Public Assessment Reports (EPARs). European Medicines Agency. (Accessed for EMA approval documentation).